A client with increased intracranial pressure is receiving Mannitol. Which finding should the nurse report to the provider?

Correct Answer: C

Rationale: Dyspnea is a concerning finding in a client receiving Mannitol as it can be a manifestation of heart failure, which is an adverse effect of the medication. The nurse should promptly notify the provider, discontinue the Mannitol, and initiate appropriate interventions to address the dyspnea and monitor the client's condition closely.

Correct Answer: A

Rationale: The correct answer is A) Remove the patch each evening. Rationale: Nitroglycerin transdermal patches are used to prevent angina episodes by providing continuous vasodilation. Removing the patch each evening helps prevent tolerance to the medication, as nitroglycerin has a short half-life and removing the patch allows for a nitrate-free period, reducing the risk of tolerance development. Tolerance can diminish the effectiveness of the medication over time, leading to decreased therapeutic benefits. Option B) Do not cut the patch in half even if angina attacks are under control is incorrect because cutting the patch can alter the drug release mechanism, leading to unpredictable dosing and potentially compromising the therapeutic effects of the medication. Option C) Remove the nitroglycerin patch for 30 minutes if a headache occurs is incorrect. Headache is a common side effect of nitroglycerin due to vasodilation, and removing the patch may worsen angina symptoms. Managing headaches with other interventions like over-the-counter pain medication or addressing underlying causes is more appropriate. Option D) Apply a new patch every 48 hours is incorrect as nitroglycerin patches are typically replaced every 24 hours to maintain a consistent therapeutic level of the medication for angina management. Educational Context: Understanding the proper administration and management of nitroglycerin patches is crucial for nursing practice to ensure optimal patient outcomes. Educating patients on the correct use of these patches, including when to remove and replace them, can enhance treatment effectiveness and prevent potential complications such as tolerance development or inadequate symptom control.

Correct Answer: D

Rationale: In this scenario, the correct answer is D) Report of anorexia. Digoxin toxicity can present with gastrointestinal symptoms like anorexia, nausea, vomiting, and abdominal pain. Anorexia is particularly common in cases of digoxin toxicity due to its impact on the gastrointestinal system. This symptom should prompt immediate assessment and potential adjustment of the digoxin dosage to prevent further complications. Option A) Bruising is not typically associated with digoxin toxicity. Bruising may be related to other factors such as blood clotting abnormalities or trauma. Option B) Report of metallic taste is not a common manifestation of digoxin toxicity. Metallic taste is more commonly associated with certain medications or oral health issues. Option C) Muscle pain is not a typical sign of digoxin toxicity. Muscle pain could be due to various reasons like strain, injury, or other medications but is not specifically linked to digoxin toxicity. Understanding the manifestations of digoxin toxicity is crucial for healthcare providers to ensure safe medication management for patients with heart failure. Regular monitoring, patient education, and prompt recognition of toxic symptoms are essential aspects of pharmacological care in such cases.

Correct Answer: C

Rationale: Ezetimibe is contraindicated in clients with active moderate-to-severe liver disorders, particularly if they are already on a statin like simvastatin. Hepatitis C is a liver condition that can be exacerbated by Ezetimibe, leading to potential complications. Therefore, the nurse should identify active hepatitis C as a contraindication to adding Ezetimibe to the client's medications.

Correct Answer: C

Rationale: Oprelvekin is a medication that stimulates platelet production. Therefore, monitoring the platelet count is essential to assess the effectiveness of this drug. The expected outcome for oprelvekin therapy is a platelet count greater than 50,000/mm^3. Changes in platelet count can indicate the response to the medication and help in adjusting the treatment plan accordingly.